This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): QLT091
Description: QLT091001 is a replacement for 11-cis-retinal which is an essential component of the retinoid–rhodopsin cycle and visual function. Two different gene mutations (Retinal pigment epithelium protein 65 [RPE65] and lecithin-retinol acyltransferase [LRAT]) result in an inadequate production of 11-cis-retinal.
Deal Structure: QLT091001 is being developed under a Co-Development agreement with Retinagenix, LLC.
In April 2006, QLT announced that it entered into an exclusive worldwide co-development and licensing agreement with Retinagenix to develop active synthetic retinoid products for the treatment of degenerative retinal diseases.
Under the terms of the agreement, QLT will be responsible to develop and commercialize the products for use in ocular and all other human diseases. Retinagenix will participate in research in support of the co-development collaboration and be eligible to receive an upfront payment of US$1.5 million, and payments upon achievement of certain development, approval and sales milestones as well as a single digit royalty on net sales.
Auxilium & QLT
In June 2014, Auxilium and QLT announced that they have entered into a definitive agreement under which Auxilium plans to merge with QLT. Under the terms of the agreement, a wholly-owned subsidiary of QLT will be...See full deal structure in Biomedtracker
Partners: Retinagenix, LLC
Additional information available to subscribers only: